KPTI vs. RNAC, CTXR, ACET, PDSB, AMLX, SCTL, GLYC, SGMT, RPTX, and IMUX
Should you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Cartesian Therapeutics (RNAC), Citius Pharmaceuticals (CTXR), Adicet Bio (ACET), PDS Biotechnology (PDSB), Amylyx Pharmaceuticals (AMLX), Societal CDMO (SCTL), GlycoMimetics (GLYC), Sagimet Biosciences (SGMT), Repare Therapeutics (RPTX), and Immunic (IMUX). These companies are all part of the "pharmaceutical preparations" industry.
Karyopharm Therapeutics (NASDAQ:KPTI) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.
Karyopharm Therapeutics currently has a consensus price target of $5.67, indicating a potential upside of 417.50%. Cartesian Therapeutics has a consensus price target of $45.00, indicating a potential upside of 86.88%. Given Karyopharm Therapeutics' higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Cartesian Therapeutics.
Karyopharm Therapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Karyopharm Therapeutics has a net margin of -97.99% compared to Cartesian Therapeutics' net margin of -845.01%. Karyopharm Therapeutics' return on equity of 0.00% beat Cartesian Therapeutics' return on equity.
In the previous week, Cartesian Therapeutics had 8 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 9 mentions for Cartesian Therapeutics and 1 mentions for Karyopharm Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.84 beat Karyopharm Therapeutics' score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.
Karyopharm Therapeutics has higher revenue and earnings than Cartesian Therapeutics.
66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 4.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 31.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Karyopharm Therapeutics received 519 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cartesian Therapeutics an outperform vote while only 72.02% of users gave Karyopharm Therapeutics an outperform vote.
Summary
Cartesian Therapeutics beats Karyopharm Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Karyopharm Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Karyopharm Therapeutics Competitors List
Related Companies and Tools
